Valuation: NEOVACS

Market Cap 4.09T 4.63T 3.87T 3.51T 6.58T 4L 6.64T 46.41T 17.89T 2L 17.4T 17.02T 7L P/E 2023 *
-
P/E 2024 -
Enterprise Value -2L -2L -2L -2L -3L -2.19Cr -3L -22.81L -9L -1.12Cr -9L -8L -3.59Cr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
1 day-8.37%
1 week+4.06%
Current month-47.45%
1 month-46.97%
3 months-85.60%
6 months-96.50%
Current year-99.76%
1 week 0.19
Extreme 0.19
0.25
1 month 0.19
Extreme 0.19
0.46
Current year 0.19
Extreme 0.19
267
1 year 0.19
Extreme 0.19
4,200
3 years 0.19
Extreme 0.19
3,20,00,000
5 years 0.19
Extreme 0.19
35,19,20,000
10 years 0.19
Extreme 0.19
35,19,20,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Date Insider Type Main position Quantity % Market Cap. Importance
27/02/21 Sell

Chief Executive Officer

25,05,144 1.3796%
23/02/21 Sell

Chief Executive Officer

63,91,053 3.5196%
23/02/21 Sell

Chief Executive Officer

11,08,947 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
-8.37%+4.06%-99.99%-100.00% 41.49T
-0.03%+3.77%+12.35%+37.22% 4.91TCr
-0.73%-0.41%+48.84%+36.72% 4.46TCr
+1.36%+6.03%+343.85%+638.73% 4.32TCr
-0.47%-0.76%+9.75%+103.07% 4.17TCr
+0.34%+0.22%+5.18%+47.36% 2.99TCr
+1.00%-1.28%+24.23%+156.93% 1.72TCr
-3.20%-3.50%+25.33%+42.43% 1.55TCr
-2.94%+6.98%+5.10% - 1.54TCr
-0.86%-4.00% - - 1.51TCr
Average -1.39%+1.42%+41.63%+120.31% 2.72TCr
Weighted average by Cap. -0.28%+1.79%+74.43%+166.43%

Financials

2023 2024
Net sales 5L 6L 5L 5L 9L 5.8Cr 9L 60.54L 23.33L 2.96Cr 22.7L 22.2L 9.53Cr 4L 5L 4L 4L 7L 4.72Cr 7L 49.25L 18.98L 2.41Cr 18.46L 18.06L 7.75Cr
Net income -87.43L -99.08L -82.73L -75.02L -1.41Cr -95Cr -1.42Cr -9.92Cr -3.82Cr -49Cr -3.72Cr -3.64Cr -156.23Cr -3.29Cr -3.73Cr -3.11Cr -2.82Cr -5.29Cr -357.89Cr -5.35Cr -37Cr -14Cr -182.75Cr -14Cr -14Cr -588.11Cr
Net Debt -2L -3L -2L -2L -4L -2.57Cr -4L -26.84L -10.35L -1.31Cr -10.06L -10L -4.23Cr -2L -2L -2L -2L -3L -2.23Cr -3L -23.28L -9L -1.14Cr -9L -9L -3.66Cr
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16
Date Price Change Volume
29/26/29 €0.2102 -8.37% 41,732
28/26/28 €0.2294 +14.64% 80,463
25/26/25 €0.2001 -17.99% 61,702
24/26/24 €0.2440 +16.19% 15,040
23/26/23 €0.2100 +3.96% 28,690
  1. Stock Market
  2. Stocks
  3. ALNEV Stock